Wheeler Bio Welcomes New Leadership in Patrick Lucy
Wheeler Bio, a prominent contract development and manufacturing organization (CDMO), has made an exciting announcement with the appointment of Patrick Lucy as its new Chief Executive Officer. With over 32 years of rich experience in the biotechnology sector, Patrick is set to bring immense value and expertise to the Wheeler Bio team.
Patrick Lucy's Impressive Background
Patrick Lucy joins Wheeler Bio after having an extensive career that includes key leadership roles at various notable biotech companies. His previous position was as President and CEO of RoslinCT US, where he successfully launched the business and led its sale just a year and a half later, achieving significant successes for its investors. His background illustrates a strong foundation, making him a valuable asset for Wheeler Bio.
Leadership Vision for Wheeler Bio
In welcoming Patrick, Jesse McCool, Ph.D., Co-Founder and Chief Scientific Officer, expressed enthusiasm about the progress Wheeler Bio is making under Patrick's leadership. "His impressive ability to scale organizations makes him an excellent choice to steer Wheeler towards its objective of becoming a fully integrated commercial-scale CDMO," McCool remarked.
Transitioning to a Fully Integrated CDMO
Patrick sees his new role as pivotal during a transformative period for Wheeler Bio. He is keen to guide the team in strengthening their scientific foundation and expanding their capabilities in clinical and commercial-stage biotechnology production. He firmly believes that Wheeler and the surrounding biotechnology ecosystem are positioned to emerge as a leading hub for innovation in the industry.
Building on Past Experiences
Before RoslinCT, Patrick made considerable contributions at Pfenex Inc., where he was a founding member, holding executive positions and leading to a successful acquisition. His background also includes valuable experiences at Repligen Corporation, Celltech Biologics, and Lonza Biologics. Each of these roles uniquely equipped him to face the rapid changes and challenges in the biotech industry today.
Expectation of Future Growth
Wheeler Bio's Co-Founders have high expectations for Patrick’s leadership. Christian Kanady highlighted Patrick's unparalleled expertise and vision, which he believes will be pivotal in shaping the company’s strategic direction as it embarks on the next chapter of growth. Together, they aim to solidify Oklahoma City as a vibrant hub for drug discovery and development.
Collaborative Efforts Moving Forward
With the support of investors and the entire Wheeler team, Patrick is excited about the potential that lies ahead. His extensive experience in managing diverse teams and driving strategic goals is expected to benefit Wheeler Bio’s future endeavors significantly.
About Wheeler Bio, Inc.
Wheeler Bio is a pioneering force in biomanufacturing, designed by a group of strategic investors and industry experts. They aim to disrupt the conventional CDMO model with innovative practices that expedite the path to clinical milestones for biotechnology innovations. Their unique hub-and-spoke operational strategy centers in Oklahoma City, aiming to revolutionize drug development speed. The technology platform known as Portable CMC® provides a simplified pathway that enhances collaboration and accelerates the journey from drug discovery to clinical manufacturing.
Frequently Asked Questions
Who is the new CEO of Wheeler Bio?
Patrick Lucy has been appointed as the new Chief Executive Officer of Wheeler Bio.
What is Patrick Lucy's previous experience?
Patrick has over 32 years in the biotechnology field, with his most recent role as CEO of RoslinCT US.
What are Wheeler Bio's core services?
Wheeler Bio offers contract development and manufacturing services, focusing on accelerating clinical milestones for biotech companies.
Where is Wheeler Bio headquartered?
Wheeler Bio operates primarily in Oklahoma City, reinforcing its commitment to the biotechnology ecosystem there.
What does Portable CMC® refer to?
Portable CMC® is Wheeler Bio's technology platform designed to simplify the process of drug development from discovery to clinical manufacturing.
